Renhe Pharmacy Co Ltd
Renhe Pharmacy Co.,Ltd produces and sells pharmaceutical products. It offers Chinese and western medicines and raw materials; and health-related products, including oral solid preparations and liquid preparations, large-volume and small-volume injections, external lotions, liniments, suppositories, ointments, and other dosage forms of drugs and health-related products. The company was founded in … Read more
Renhe Pharmacy Co Ltd (000650) - Net Assets
Latest net assets as of September 2025: CN¥7.04 Billion CNY
Based on the latest financial reports, Renhe Pharmacy Co Ltd (000650) has net assets worth CN¥7.04 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.10 Billion) and total liabilities (CN¥1.06 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.04 Billion |
| % of Total Assets | 86.92% |
| Annual Growth Rate | 22.4% |
| 5-Year Change | 21.31% |
| 10-Year Change | 161.68% |
| Growth Volatility | 82.5 |
Renhe Pharmacy Co Ltd - Net Assets Trend (1993–2024)
This chart illustrates how Renhe Pharmacy Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Renhe Pharmacy Co Ltd (1993–2024)
The table below shows the annual net assets of Renhe Pharmacy Co Ltd from 1993 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.81 Billion | +2.28% |
| 2023-12-31 | CN¥6.65 Billion | +3.62% |
| 2022-12-31 | CN¥6.42 Billion | +8.35% |
| 2021-12-31 | CN¥5.93 Billion | +5.64% |
| 2020-12-31 | CN¥5.61 Billion | +28.92% |
| 2019-12-31 | CN¥4.35 Billion | +11.16% |
| 2018-12-31 | CN¥3.91 Billion | +12.74% |
| 2017-12-31 | CN¥3.47 Billion | +8.36% |
| 2016-12-31 | CN¥3.20 Billion | +23.21% |
| 2015-12-31 | CN¥2.60 Billion | +20.30% |
| 2014-12-31 | CN¥2.16 Billion | +11.51% |
| 2013-12-31 | CN¥1.94 Billion | +13.25% |
| 2012-12-31 | CN¥1.71 Billion | +49.90% |
| 2011-12-31 | CN¥1.14 Billion | +25.22% |
| 2010-12-31 | CN¥912.05 Million | +6.40% |
| 2009-12-31 | CN¥857.16 Million | +180.48% |
| 2008-12-31 | CN¥305.60 Million | +29.80% |
| 2007-12-31 | CN¥235.44 Million | +20.92% |
| 2006-12-31 | CN¥194.71 Million | +315.30% |
| 2005-12-31 | CN¥46.88 Million | -72.27% |
| 2004-12-31 | CN¥169.04 Million | -29.02% |
| 2003-12-31 | CN¥238.17 Million | -29.69% |
| 2002-12-31 | CN¥338.74 Million | +2.16% |
| 2001-12-31 | CN¥331.58 Million | -3.98% |
| 2000-12-31 | CN¥345.32 Million | +32.06% |
| 1999-12-31 | CN¥261.49 Million | +11.86% |
| 1998-12-31 | CN¥233.76 Million | +46.61% |
| 1997-12-31 | CN¥159.44 Million | +11.45% |
| 1996-12-31 | CN¥143.07 Million | +179.01% |
| 1995-12-31 | CN¥51.28 Million | +5.40% |
| 1994-12-31 | CN¥48.65 Million | +276.53% |
| 1993-12-31 | CN¥12.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Renhe Pharmacy Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 354378027100.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.54 Billion | 57.40% |
| Common Stock | CN¥1.40 Billion | 22.68% |
| Other Components | CN¥1.23 Billion | 19.92% |
| Total Equity | CN¥6.17 Billion | 100.00% |
Renhe Pharmacy Co Ltd Competitors by Market Cap
The table below lists competitors of Renhe Pharmacy Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CT Real Estate Investment Trust
PINK:CTRRF
|
$777.74 Million |
|
Nano Nuclear Energy Inc. Common Stock
NASDAQ:NNE
|
$777.85 Million |
|
PATTIES FOODS - Frankfurt Stock Exchang
F:PH4
|
$777.98 Million |
|
Qurient Co. Ltd
KQ:115180
|
$778.59 Million |
|
IntegraFin Holdings plc
PINK:IHPGF
|
$777.24 Million |
|
SpartanNash Company
F:SRJ
|
$777.16 Million |
|
Sensirion Holding AG
SW:SENS
|
$776.75 Million |
|
Workspace Group plc
PINK:WKPPF
|
$776.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Renhe Pharmacy Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,993,036,906 to 6,173,659,007, a change of 180,622,101 (3.0%).
- Net income of 481,911,685 contributed positively to equity growth.
- Dividend payments of 279,931,173 reduced retained earnings.
- Share repurchases of 39,930,992 reduced equity.
- Other comprehensive income decreased equity by 452,987,918.
- Other factors increased equity by 471,560,499.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥481.91 Million | +7.81% |
| Dividends Paid | CN¥279.93 Million | -4.53% |
| Share Repurchases | CN¥39.93 Million | -0.65% |
| Other Comprehensive Income | CN¥-452.99 Million | -7.34% |
| Other Changes | CN¥471.56 Million | +7.64% |
| Total Change | CN¥- | 3.01% |
Book Value vs Market Value Analysis
This analysis compares Renhe Pharmacy Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.33x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 420.63x to 1.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-12-31 | CN¥0.01 | CN¥5.92 | x |
| 1994-12-31 | CN¥0.05 | CN¥5.92 | x |
| 1995-12-31 | CN¥0.06 | CN¥5.92 | x |
| 1996-12-31 | CN¥0.16 | CN¥5.92 | x |
| 1997-12-31 | CN¥0.17 | CN¥5.92 | x |
| 1998-12-31 | CN¥0.25 | CN¥5.92 | x |
| 1999-12-31 | CN¥0.28 | CN¥5.92 | x |
| 2000-12-31 | CN¥0.38 | CN¥5.92 | x |
| 2001-12-31 | CN¥0.36 | CN¥5.92 | x |
| 2002-12-31 | CN¥0.37 | CN¥5.92 | x |
| 2003-12-31 | CN¥0.26 | CN¥5.92 | x |
| 2004-12-31 | CN¥0.18 | CN¥5.92 | x |
| 2005-12-31 | CN¥0.05 | CN¥5.92 | x |
| 2006-12-31 | CN¥0.21 | CN¥5.92 | x |
| 2007-12-31 | CN¥0.26 | CN¥5.92 | x |
| 2008-12-31 | CN¥0.33 | CN¥5.92 | x |
| 2009-12-31 | CN¥0.83 | CN¥5.92 | x |
| 2010-12-31 | CN¥1.10 | CN¥5.92 | x |
| 2011-12-31 | CN¥0.94 | CN¥5.92 | x |
| 2012-12-31 | CN¥1.32 | CN¥5.92 | x |
| 2013-12-31 | CN¥1.50 | CN¥5.92 | x |
| 2014-12-31 | CN¥1.62 | CN¥5.92 | x |
| 2015-12-31 | CN¥1.95 | CN¥5.92 | x |
| 2016-12-31 | CN¥2.22 | CN¥5.92 | x |
| 2017-12-31 | CN¥2.45 | CN¥5.92 | x |
| 2018-12-31 | CN¥2.75 | CN¥5.92 | x |
| 2019-12-31 | CN¥3.07 | CN¥5.92 | x |
| 2020-12-31 | CN¥4.02 | CN¥5.92 | x |
| 2021-12-31 | CN¥3.78 | CN¥5.92 | x |
| 2022-12-31 | CN¥4.10 | CN¥5.92 | x |
| 2023-12-31 | CN¥4.33 | CN¥5.92 | x |
| 2024-12-31 | CN¥4.46 | CN¥5.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Renhe Pharmacy Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.81%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.83%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.21x
- Recent ROE (7.81%) is above the historical average (6.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | 99.11% | 10.14% | 0.97x | 10.04x | CN¥11.51 Million |
| 1994 | 27.66% | 10.18% | 0.77x | 3.55x | CN¥8.59 Million |
| 1995 | 34.15% | 10.89% | 0.94x | 3.33x | CN¥12.38 Million |
| 1996 | 10.47% | 8.84% | 0.63x | 1.89x | CN¥672.06K |
| 1997 | 10.27% | 12.02% | 0.49x | 1.74x | CN¥431.12K |
| 1998 | 12.11% | 14.69% | 0.54x | 1.54x | CN¥4.93 Million |
| 1999 | 10.60% | 11.75% | 0.50x | 1.82x | CN¥1.58 Million |
| 2000 | 6.31% | 9.23% | 0.36x | 1.89x | CN¥-12.74 Million |
| 2001 | -4.37% | -6.43% | 0.32x | 2.15x | CN¥-47.64 Million |
| 2002 | 2.59% | 3.97% | 0.29x | 2.24x | CN¥-25.11 Million |
| 2003 | -42.19% | -35.68% | 0.41x | 2.85x | CN¥-124.30 Million |
| 2004 | -37.22% | -22.44% | 0.47x | 3.55x | CN¥-79.82 Million |
| 2005 | -277.16% | -48.64% | 0.59x | 9.73x | CN¥-134.63 Million |
| 2006 | 66.92% | 522.39% | 0.09x | 1.40x | CN¥110.83 Million |
| 2007 | 16.64% | 5.03% | 2.52x | 1.31x | CN¥15.63 Million |
| 2008 | 22.96% | 8.01% | 2.00x | 1.43x | CN¥39.60 Million |
| 2009 | 19.70% | 17.17% | 0.93x | 1.24x | CN¥83.08 Million |
| 2010 | 25.12% | 16.06% | 0.92x | 1.69x | CN¥132.13 Million |
| 2011 | 26.89% | 13.71% | 1.37x | 1.43x | CN¥188.66 Million |
| 2012 | 15.76% | 12.24% | 1.00x | 1.29x | CN¥93.39 Million |
| 2013 | 10.63% | 10.79% | 0.77x | 1.28x | CN¥11.54 Million |
| 2014 | 14.80% | 13.35% | 0.87x | 1.28x | CN¥97.61 Million |
| 2015 | 16.38% | 15.50% | 0.80x | 1.32x | CN¥152.40 Million |
| 2016 | 13.53% | 10.44% | 0.92x | 1.40x | CN¥97.20 Million |
| 2017 | 12.64% | 9.89% | 0.92x | 1.39x | CN¥79.37 Million |
| 2018 | 14.93% | 11.50% | 0.95x | 1.36x | CN¥167.31 Million |
| 2019 | 14.13% | 11.74% | 0.92x | 1.31x | CN¥157.27 Million |
| 2020 | 11.44% | 13.56% | 0.68x | 1.24x | CN¥72.89 Million |
| 2021 | 12.58% | 13.47% | 0.71x | 1.31x | CN¥136.30 Million |
| 2022 | 10.01% | 11.15% | 0.68x | 1.33x | CN¥351.25K |
| 2023 | 9.47% | 11.27% | 0.68x | 1.24x | CN¥-32.05 Million |
| 2024 | 7.81% | 11.83% | 0.54x | 1.21x | CN¥-135.45 Million |
Industry Comparison
This section compares Renhe Pharmacy Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,330,935,178
- Average return on equity (ROE) among peers: -1.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Renhe Pharmacy Co Ltd (000650) | CN¥7.04 Billion | 99.11% | 0.15x | $777.45 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |